Comparing uptake across breast, cervical and bowel screening at an individual level: a retrospective cohort study by McCowan, Colin et al.
ARTICLE
Epidemiology
Comparing uptake across breast, cervical and bowel screening
at an individual level: a retrospective cohort study
Colin McCowan1, Paula McSkimming2, Richard Papworth2, Marie Kotzur3, Alex McConnachie2, Sara Macdonald4, Sally Wyke5,
Emilia Crighton6, Christine Campbell7, David Weller7, Robert J. C. Steele8 and Kathryn A. Robb3
BACKGROUND: We investigated demographic and clinical predictors of lower participation in bowel screening relative to breast
and cervical screening.
METHODS: Data linkage study of routinely collected clinical data from 430,591 women registered with general practices in the
Greater Glasgow & Clyde Health Board. Participation in the screening programmes was measured by attendance at breast or
cervical screening or the return of a bowel screening kit.
RESULTS: 72.6% of 159,993 women invited attended breast screening, 80.7% of 309,899 women invited attended cervical
screening and 61.7% of 180,408 women invited completed bowel screening. Of the 68,324 women invited to participate in all three
screening programmes during the study period, 52.1% participated in all three while 7.2% participated in none. Women who
participated in breast (OR= 3.34 (3.21, 3.47), p < 0.001) or cervical (OR= 3.48 (3.32, 3.65), p < 0.001) were more likely to participate
in bowel screening.
CONCLUSION: Participation in bowel screening was lower than breast or cervical for this population although the same
demographic factors were associated with uptake, namely lower social deprivation, increasing age, low levels of comorbidity and
prior non-malignant neoplasms. As women who complete breast and cervical are more likely to also complete bowel screening,
interventions at these procedures to encourage bowel screening participation should be explored.
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BACKGROUND
Screening can reduce deaths from cancer if people are willing to
participate. Population-based surveys in the USA and UK have
found public enthusiasm for cancer screening to be around
90%,1,2 but uptake of screening for women in Scotland is much
lower, at 72% for breast, 73% for cervical but only 60% for
bowel.3–5 The differential between public support and participa-
tion is most obviously seen in bowel screening and a better
understanding of why it fails to achieve the same uptake rates of
breast and cervical screening is needed.
In Scotland, women are invited to participate in three
national cancer screening programmes. For breast screening,
women are invited to attend for mammogram every 3 years
between the ages of 50 and 69 years. For cervical screening,
since June 2016 women are invited between the ages of 25–49
every 3 years and women aged 50–64 are invited every 5 years,
but prior to that women aged 20–59 years were invited to
cervical screening every 3 years. For bowel screening, men and
women aged 50–74 are invited to complete the home-based
guaiac faecal occult blood test (FOB test) every 2 years, although
this was replaced by a Faecal Immunochemical Test (FIT) in
November 2017.
The lower uptake of bowel screening has not been extensively
explored in relation to the higher uptake achieved for breast and
cervical screening among the same women. A survey of 890
women reported whether they had ever completed breast,
cervical or colorectal screening with responses of 90, 83 and
67% for those who were eligible.6 Social deprivation was the only
common factor associated with lower participation across the
three programmes and women who did breast or cervical
screening were more likely to do colorectal, than those who did
not. However less than half the women surveyed were eligible for
colorectal screening. One survey in the UK focussed on self-
reported cervical and breast screening uptake and found that 84%
had ever participated in breast or cervical screening, but that 3%
had never done either. The authors also reported differential
uptake by markers of social deprivation for both programmes and
for ethnicity for cervical screening.7 A more recent paper
examining socio-economic inequalities across England on uptake
of cervical and breast screening reported that there was still
differential uptake of cervical screening by SES but not breast
screening.8 Our study examined factors associated with actual
screening uptake (self-report tends to overestimate screening
participation)7 to provide a better understanding of the profiles of
www.nature.com/bjc
Received: 25 April 2019 Accepted: 16 August 2019
Published online: 4 September 2019
1School of Medicine, University of St Andrews, St Andrews KY16 9TF, UK; 2Robertson Centre for Biostatistics, Institute of Health & Wellbeing, University of Glasgow, Glasgow G12
8QQ, UK; 3Institute of Health & Wellbeing, University of Glasgow, Glasgow G120XH, UK; 4Institute of Health & Wellbeing, University of Glasgow, Glasgow G129LX, UK; 5Institute of
Health & Wellbeing, University of Glasgow, Glasgow G128RS, UK; 6NHS Greater Glasgow and Clyde, Gartnavel Royal Hospital, Glasgow G120XH, UK; 7Usher Institute, University of
Edinburgh, Edinburgh EH8 9AG, UK and 8School of Medicine, University of Dundee, Dundee DD14HN, UK
Correspondence: Colin McCowan (cm434@st-andrews.ac.uk)
© The Author(s) 2019 Published by Springer Nature on behalf of Cancer Research UK
women engaging in none, some or all forms of cancer screening.
A better understanding of the numbers and characteristics of
women in these groups will help in informing the development of
interventions to increase bowel screening uptake. Our study
aimed to investigate demographic and clinical factors associated
with the lower participation in bowel screening relative to breast
and cervical screening using linked data.
METHODS
The study is a cross-sectional analysis of national cancer screening
programme and health-related databases available for over 1.3
million residents of the Greater Glasgow area, Scotland, UK. In
Scotland, universal healthcare is provided by a publicly funded
system the National Health Service (NHS), and managed at a local
level by regional health boards. Each patient registered with a
general practice within the Greater Glasgow and Clyde (GGC)
health board has a unique 10-digit identifier called the community
health index number (CHI), which allows data linkage of all NHS
encounters including any participation in the three cancer
screening programmes. The linked data were held within the
NHS Greater Glasgow & Clyde (NHSGGC) Safe Haven.
We examined records of all female patients listed in the breast,
cervical and bowel screening programmes in NHSGGC for the
period 1 January 2009 to 31 December 2013. Patients were
identified as invited to the three cancer screening programmes if
there was a record of an invitation being sent or the individual
participating in the programme. We used the term ‘completed’ if
people attended breast or cervical or returned the bowel
screening test kit. Data on invitations and completion of each
programme were linked to hospital discharge records, use of anti-
depressants from the National Prescribing Information System,9
the presence of learning disabilities recorded in General Practice
local enhanced service data, and demographic data including age,
nursing home residence and socio-economic status measured by
the postcode based Scottish Index of Multiple Deprivation (SIMD)
quintiles.10 All identifiers were removed from the original data
sources and replaced with a project specific pseudonymous
identifier before the research team were given access to the data
via the Glasgow Safe Haven secure analytical platform.
A Charlson Index of comorbidity for each individual was
calculated based on diagnostic ICD-10 codes within hospital
discharge records.11 Prior malignant neoplasms were also identi-
fied from hospital discharge records as were non-malignant
neoplasm, which included non-cancerous, in situ and other groups
of neoplasms.
Data received from the cancer screening programmes included
information on invites to the cervical and breast programmes and
test kits sent out for the bowel programme. All attendances at
breast and cervical screening and return of bowel screening test
kits were also reported. All of these contacts with the screening
programme were dated but there was no indication of which cycle
of screening each test was for or whether it was an initial
invitation or test kit or a follow-on invitation. We therefore
focussed on any participation in each programme within the study
period as our outcome of interest as a proxy for coverage, which is
defined as participation in a screening programme within a 3 year
period.8
Statistical analysis
Data were analysed descriptively overall and by group (completed
screening and did not complete screening) with means and
standard deviations for continuous outcomes and number and
percentage for categorical outcomes. Group comparisons were
carried out using t-tests for continuous data and Fisher’s Exact
tests unless otherwise stated.
To identify factors that may influence whether a woman will
complete cancer screening or not, multivariable logistic regression
models were created with completed screening as the outcome
and the following variables as predictors: age (per 10 Years); SIMD
quintiles; care home resident; learning disabled; cancer diagnosis
ever; Charlson Comorbidity Index Score Category (0, 1, 2+). Odds
ratios for between-group differences were calculated with 95%
confidence intervals (CIs) and p-values. The multivariable models
were then extended to include interaction terms between SIMD
and each of the other predictor variables as well as the interaction
between completing breast and cervical screenings. Similar
models were constructed for the cohort of women who were
eligible for all three screenings with completed bowel as the
outcome and also the additional adjustments of completed breast
screening and completed cervical screening.
All statistical analyses were performed using SAS version 9.3.
RESULTS
Four hundred and thirty thousand five hundred and ninety one
women were invited to take part in at least one of the screening
programmes during 2009–2013. One hundred and sixteen
thousand two hundred and twelve (72.6%) women attended for
breast screening out of 159,993 invited over the period, 250,056
(80.7%) women attended cervical screening from 309,899 invited
and 111,235 (61.7%) women completed bowel screening from
180,408 invited. See Table 1 for a summary of demographic
characteristics by screening programme.
Table 1. Characteristics of all women invited to cancer screening
programmes in NHS Greater Glasgow and Clyde 2009–2013
Breast Cervical Bowel
Eligible population 159,993 309,899 180,408
Ever screened between
2009–2013 (%)
116,212 (72.6) 250,056 (80.7) 111,235 (61.7)
Age of women screening (%)
<20 0 1210 (95.0) 0
20–29 0 70,820 (72.8) 0
30–39 0 59,070 (84.4) 0
40–49 85 (55.9) 66,790 (85.1) 0
50–59 65,087 (72.1) 46,759 (81.7) 57,182 (59.7)
60–69 44,105 (72.8) 5304 (96.6) 37,886 (66.7)
70+ 6935 (77.3) 103 (100.0) 16,167 (58.0)
SIMD Quintiles of socio-economic deprivation (%)
1 (most deprived) 32,727 (63.2) 87,677 (79.7) 31,800 (52.3)
2 19,288 (71.0) 42,767 (79.8) 18,269 (59.3)
3 16,700 (74.6) 36,846 (80.2) 15,601 (63.1)
4 18,276 (79.0) 33,642 (79.5) 16,832 (68.6)
5 (most affluent) 29,221 (82.4) 49,124 (84.6) 28,733 (72.7)
Care home resident 234 (39.7) 212 (68.4) 235 (21.0)
Learning disability
registered
328 (52.1) 347 (34.4) 266 (39.6)
Long term anti-
depressant use
22,475 (67.2) 43,558 (86.5) 21,246 (57.4)
Previous neoplasm (%)
None 99,312 (73.3) 233,061 (80.3) 92,228 (60.9)
Non-malignant 9037 (77.6) 11,107 (87.8) 8660 (69.0)
Malignant 7863 (61.3) 5888 (85.0) 10,347 (62.6)
Charlson Index of comorbidity during study period (%)
0 75,905 (74.1) 210,015 (79.7) 68,803 (61.4)
1–2 31392 (72.7) 34,512 (86.9) 31,722 (64.1)
3+ 8915 (62.0) 5529 (84.0) 10,710 (56.9)
Comparing uptake across breast, cervical and bowel screening at an. . .
C McCowan et al.
711
1
2
3
4
5
6
7
8
9
0
()
;,:
Of the women who participated in each screening programme,
30,371 (26.1%) attended more than one breast screening, 75,222
(30.1%) attended more than one cervical screening and 62,385
(56.1%) returned more than one bowel screening test.
Six hundred and twenty nine women were identified as having
a learning disability and were invited for breast screening, with
328 (52.1%) participating. Similarly, for cervical screening, 1008
women with a learning disability were invited with 347 (34.4%)
participating and for bowel screening, 672 women were sent a kit
and 266 (39.6%) participated.
Five hundred and ninety women were identified as being care
home residents and invited for breast screening with 234 (39.7%)
participating. Similarly, for cervical screening, 310 women living in
care homes were invited with 212 (68.4%) participating, and for
bowel screening, 1118 women were invited with 235 (21.0%)
participating.
We also examined participation in the screening programmes
of women with a diagnosis of depression, where any prescrip-
tion of an anti-depressant in prescribing records during the
study period was taken as a proxy for a clinical diagnosis. 33,427
women on anti-depressant medication were invited for breast
screening with 22,475 (67.2%) participating, 50,351 women on
anti-depressant medication were invited for cervical screening
with 43,558 (86.5%) participating and 37,026 women on anti-
depressant medication were invited for bowel screening with
21,246 (57.4%) participating.
Multivariable logistic regression models showed that increasing
age, socio-economic status, history of a prior non-malignant
neoplasm and low level of comorbidity were associated with
higher participation in all three screening programmes (see
Table 2). Patients resident in a care home or with a learning
disability were less likely to participate in all three programmes.
The presence of prior malignant cancer reduced the likelihood of
participation in breast and cervical but increased the likelihood for
bowel screening. Higher levels of comorbidity (Charlson Index of
3 or more) reduced participation in breast and bowel screening
but had no effect on cervical screening.
Sixty eight thousand three hundred and twenty four women
were invited to participate in all three screening programmes:
35,595 (52.1%) participated in all three programmes at least once,
and 4934 (7.2%) participated in none during the study period
2009–2013. One thousand and sixty-four women (1.6%) partici-
pated in bowel screening only, 7601 (11.1%) participated in bowel
screening and also one of breast or cervical screening and 19,130
(28.0%) participated in breast and/or cervical screening but not
bowel screening.
Comparing across screening programmes the absolute differ-
ence between bowel and breast and cervical was 11% (65 vs 76%)
and 19% (65 vs 84%). Interestingly across several predictors of
uptake (SIMD, younger age) these differences were broadly
maintained within the different categories.
The characteristics of women who were eligible for all three
programmes, and participated in all three, is shown in Table 3.
A high proportion of women who attended breast or cervical
also participated in bowel screening, at 73.5 and 71.1%,
respectively, although 19,130 women (28%) participated in
breast and/or cervical screening but not bowel. Older women
and increasing affluence saw higher proportions of women
participate in screening. Compared to those with no prior
neoplasms, higher proportions of women with prior non-
malignant neoplasms participated in all three programmes
although women with prior malignant cancers had higher
participation in cervical and bowel but lower for breast. Women
with lower levels of comorbidity had lower participation in
cervical and bowel screening but higher participation for breast.
Women with a high level of comorbidity had lower participation
across all three programmes.
A multivariable logistic regression on completion of bowel
screening (Table 4) showed increased participation among older
women (OR= 1.79 (1.70, 1.88) per additional 10 years, p < 0.001),
more affluent women (p < 0.001 see Table 4 for ratios across each
category), those with previous non-malignant (OR= 1.18 (1.09,
1.27), p < 0.001) or malignant neoplasms (OR= 1.43 (1.30, 1.56),
p < 0.001) compared to no previous history, and those with a low
level of comorbidity (OR= 1.08 (1.03, 1.12), p < 0.001) compared to
women with no comorbid illness. Women who participated in
breast (OR= 3.34 (3.21, 3.47), p < 0.001) or cervical screening
(OR= 3.48 (3.32, 3.65), p < 0.001) were also much more likely to
participate in bowel screening. Women were less likely to
participate in bowel screening if they were a care home resident
(OR= 0.51 (0.30, 0.85), p= 0.010) or had high levels of comorbid-
ity (OR= 0.89 (0.82, 0.97), p= 0.008).
Table 2. Multivariable Logistic Regression Models for women participating in cancer screening programmes
Breast Cervical Bowel
Eligible population 159,993 309,899 180,408
Age (per additional 10 years) 1.17 (1.15, 1.19) 1.26 (1.25, 1.27) 1.11 (1.09. 1.12)
Scottish Index of Multiple Deprivation Quintiles (%)
1 (poorest) 0.38 (0.36, 0.39) 0.76 (0.74, 0.79) 0.41 (0.40, 0.42)
2 0.53 (0.51, 0.55) 0.77 (0.74, 0.79) 0.54 (0.52, 0.56)
3 0.64 (0.61, 0.66) 0.79 (0.76, 0.81) 0.64 (0.62, 0.66)
4 0.81 (0.78, 0.85) 0.74 (0.72, 0.77) 0.83 (0.80, 0.85)
5 (most affluent) Reference Level
Care home resident 0.28 (0.24, 0.33) 0.56 (0.44, 0.73) 0.16 (0.14, 0.19)
Learning disability registered 0.55 (0.47, 0.65) 0.12 (0.10, 0.14) 0.55 (0.47, 0.64)
Previous neoplasm (%)
None Reference Level
Non-malignant 1.29 (1.23, 1.35) 1.50 (1.42, 1.59) 1.44 (1.38, 1.50)
Malignant 0.62 (0.59, 0.65) 0.90 (0.83, 0.97) 1.09 (1.05, 1.14)
Charlson Index of comorbidity (%)
0 Reference Level
1–2 1.05 (1.02, 1.08) 1.45 (1.41, 1.50) 1.17 (1.15, 1.20)
3+ 0.75 (0.72, 0.78) 1.06 (0.99, 1.15) 0.87 (0.84, 0.90)
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A further model examined interactions between SIMD, patient
characteristics and their association with participation in cancer
screening. There were significant interactions with age (p= 0.002),
learning disabled status (p= 0.008) and whether the woman
attended cervical screening (p= 0.001). For all three, the odds of
participating in bowel screening were increased if a woman lived
in a more affluent area. The interaction between participating in
breast and cervical screening was also significant (p < 0.001)
indicating that whether a woman attends one or both of these
screenings increased their odds of attending bowel screening as
well (data not reported).
DISCUSSION
Our findings confirm that participation in bowel screening was
lower than for the breast or cervical screening programmes in
women eligible for all three. Our results also highlight that while
93% participate in at least one programme and 52% participate
in all three, 7% of women do not participate in any of the
programmes.
The impact of demographic, clinical and socio-economic
factors on participation in all programmes was similar. Lower
participation associated with increased deprivation followed
known patterns,8,12 although the association seemed less
pronounced for cervical screening. Differences we report could
be in part due to the dynamics of screening modalities where
women may find it easier to participate in a “passive” screening
procedure (i.e. having a mammogram) rather than self-
completion (e.g. FOBT at home or HPV self-sampling). Our data
also relate well to the self-reported data from Lo et al.6 that
women are less likely to participate in bowel than breast or
cervical. We did not directly compare participation in breast vs
cervical as our focus was on bowel, but found 7% who did no
screening compared to the self-reported figure of 3% for only
these two programmes.7 Our analysis showed women with
learning disabilities, resident in care or nursing homes, have
much lower levels of participation. Women with depression,
identified by use of anti-depressants, had lower levels of
participation in bowel and breast but not cervical screening.
A further, more detailed analysis of the impact of individual
morbidity and multi-morbidity on participation rates could
provide more information.
We believe this is the first study to report on participation across
three separate cancer screening programmes for women at an
individual level for a large geographically defined population. We
examined the entire population in Glasgow eligible for screening
and although Glasgow has higher proportions of women living in
deprived areas than the rest of Scotland we know of no reason
why women’s attitudes to screening may be different in Glasgow
to elsewhere. We were unable to match invitation and atten-
dances to cycles of each programme, which may reflect our
reporting of slightly higher participation in each of the screening
programmes than published data for Scotland. This also meant
eligibility for the programmes was based on which women were
invited or completed screening, which included women outside
the recommended age criteria for each programme, although this
was only 2% of women attending for cervical screening and 4%
for breast screening.
We have conducted exploratory qualitative interviews with
women with different screening histories. These data show that
women who participated in breast and cervical screening but not
colorectal cancer screening, were more worried about outcomes
from colorectal than breast or cervical cancer, that they thought
there was less need to screen for colorectal cancer as it could be
picked up symptomatically more easily than breast or cervical
cancer, they were concerned about how to do the actual test, and
that it was easier to forget or delay. A detailed presentation of
these data is currently under review.
Table 3. Characteristics of cohort eligible for all three cancer
screening programmes
Breast Cervical Bowel
Eligible population 68,324 68,324 68,324
Ever screened between
2009–2013 (% of eligible
population)
51,798 (75.8) 57,250 (83.8) 44,260 (64.8)
Also completed bowel
screening (% of breast
and cervical attendees)
38,097 (73.5) 40,694 (71.1) 44,260 (100.0)
Age of attendees (%)
50–59 45,632 (74.8) 50,176 (82.3) 38,531 (63.2)
60+ 6166 (84.1) 7074 (96.5) 5729 (78.1)
SIMD Quintiles of socio-economic deprivation (%)
1 (most deprived) 14,158 (66.6) 16,819 (79.2) 11,818 (55.6)
2 8172 (74.1) 9131 (82.8) 6865 (62.3)
3 7350 (77.1) 7993 (83.9) 6254 (65.6)
4 8070 (81.3) 8584 (86.4) 6988 (70.4)
5 (most affluent) 14,048 (84.7) 14,723 (88.8) 12,335 (74.4)
Care home resident 40 (47.6) 41 (48.8) 28 (33.3)
Learning disability
registered
120 (51.3) 77 (32.9) 88 (37.6)
Long term anti-
depressant use
10,341 (70.1) 12,406 (84.1) 8935 (60.6)
Previous neoplasm (%)
None 46,490 (76.5) 51,011 (83.6) 39,280 (64.3)
Non-malignant 3245 (78.9) 3560 (86.5) 2847 (69.2)
Malignant 1863 (59.0) 2679 (84.9) 2133 (67.6)
Charlson Index of comorbidity (%)
0 37,851 (77.4) 40,601 (83.0) 31,582 (64.6)
1–2 11,653 (74.2) 13,584 (86.4) 10,445 (66.5)
3+ 2294 (62.3) 3065 (83.2) 2233 (60.6)
Table 4. Multivariable Logistic Regression Models for cohort of
women eligible for all three cancer screening programmes
Odds ratio 95%CI p-value
Eligible population, N= 68 234
Age (per additional 10 years) 1.79 (1.70, 1.88) <0.001
SIMD Quintiles of socio-economic deprivation (%)
1 (most deprived) 0.56 (0.53, 0.58) <0.001
2 0.67 (0.63, 0.71) <0.001
3 0.75 (0.70, 0.79) <0.001
4 0.87 (0.82, 0.92)
5 (most affluent) Reference Level
Care home resident 0.50 (0.30, 0.84) 0.008
Previous cancer (%)
None Reference Level
Non-malignant 1.18 (1.09, 1.27) <0.001
Malignant 1.43 (1.30, 1.56) <0.001
Charlson Index of comorbidity (%)
0 Reference Level
1–2 1.08 (1.03, 1.12) <0.001
3+ 0.89 (0.82, 0.97) 0.008
Attended breast screening 3.34 (3.21, 3.47) <0.001
Attended cervical screening 3.48 (3.32, 3.65) <0.001
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Our data suggest that women are more likely to complete
bowel screening if they participate in another screening
programme. Although from this quantitative study it is not clear
why bowel screening uptake should be lower, breast and cervical
screening programmes could be used as a vehicle to promote
participation in bowel screening. It should be noted that there was
a core of women who did not participate in any programme and it
will be important to establish if this reflects informed choice or a
failure of current screening invitation strategies to engage with
this group. Our data also suggest that women with learning
disabilities or who are resident in care homes are much less likely
to participate in all screening programmes and clinical care teams
should think how best to ensure screening is undertaken in these
populations where appropriate.
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